MarginsXMarginsX
Home › Markets › Health Care › PCRX

Pacira BioSciences Inc. (PCRX)

PCRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$36.48
+0.05% on the day
Market cap
$1.5B
Small cap
Revenue · 2025
$726.4M
+3.6% on 2024
Net income · 2025
$7.0M
1.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1396814/000162828026012297/0001628280-26-012297-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerPCRX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2011
SEC CIK0001396814
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$726.4M
Net income$7.0M
Operating income$19.2M
Net margin1.0%
Operating margin2.6%
Revenue growth+3.6%
Cash$158.5M
Total assets$1.3B
P/E (computed)207.9×
P/S (computed)2.0×

Warning signs

Cash runway
Cash-flow positive
$247.0M cash at September 30, 2026
Share count, 1 year
-6.8%
2025-11-05 to 2026-11-04 · -13.7% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$2.5M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$247.0M cash; operating cash flow $44.2M a quarter.Report 2026-09-30
Shares outstanding40,094,660 (2026-11-04); 43,021,275 a year earlier; 46,437,704 three years earlier.Cover page 2026-11-04
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Short Hills, New Jersey, United StatesPCAOB Form AP 2026-03-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $2.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$176.7M$28.5M$50.1M$247.0M$293.6M$743.3M10-Q 2026-11-05
Q2 2026
2026-06-30
$192.4M$4.7M$57.5M$205.9M$363.1M$746.2M10-Q 2026-08-04
Q1 2026
2026-03-31
$177.4M$2.9M$25.7M$144.3M$367.7M$734.9M10-Q 2026-04-30
Q4 2025
2025-12-31
$196.9M$1.6M$43.7M$158.5M$372.2M$726.4M10-K 2026-02-26
Q3 2025
2025-09-30
$179.5M$5.4M$60.8M$147.6M$376.7M$716.8M10-Q 2026-11-05
Q2 2025
2025-06-30
$181.1M-$4.8M$12.0M$300.5M$580.5M$705.8M10-Q 2026-08-04
Q1 2025
2025-03-31
$168.9M$4.8M$35.5M$283.6M$583.4M$702.8M10-Q 2026-04-30
Q4 2024
2024-12-31
$187.3M$16.0M$33.1M$276.8M$585.3M$701.0M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52014-04-09
Latest annual report
10-K - PCRX - 12.31.2025
10-K2026-02-26
Latest quarterly / interim
10-Q - PCRX - 9.30.2026
10-Q2026-11-05
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-06-04

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.1%
1 month+0.4%
3 months+57.3%
Year to date+40.9%
1 year+54.4%
From 52-week high-0.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
RAPPRapport Therapeutics Inc.$24.82-5.09%$1.5B
NBTXNanobiotix S.A.$28.54-6.90%$1.5B
KRSAKorsana Biosciences Inc.$32.68+3.25%$1.5B
PAHCPhibro Animal Health Corporation$35.02-2.64%$1.4B
SLSSELLAS Life Sciences Group Inc.$7.47-4.96%$1.5B
QUREuniQure N.V.$21.88-8.11%$1.5B
DMRADamora Therapeutics Inc.$22.50+4.14%$1.4B
LBRXLB Pharmaceuticals Inc$42.99-0.05%$1.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier